European Innovation Council

Basemark Oy is a technology company based in Espoo, Finland, specializing in performance measurement and augmented reality software for various industries, particularly in automotive applications. Founded in 2015, Basemark develops a suite of benchmarking tools that include Basemark ES 3.1 for graphics performance comparisons, Basemark OS II for system-level performance assessment of smartphones and tablets across multiple platforms, and Basemark X for evaluating gaming and graphics performance. Additionally, it offers Browsermark, which tests browser performance on a range of devices, and Basemark CL for measuring OpenCL implementations. In the automotive sector, Basemark provides a comprehensive suite of augmented reality development tools, enabling original equipment manufacturers and suppliers to create and deploy advanced AR applications for vehicle functions. These tools encompass features such as augmented reality navigation, head-up displays, and AI-based spatial computing, enhancing safety and performance in software-defined vehicles.

Neuro Event Labs Oy is a Finnish medical technology company founded in 2015 and based in Tampere. The company specializes in developing artificial intelligence-powered software that monitors epilepsy patients both at home and in clinical settings. Its primary product collects and analyzes accurate data on epilepsy seizures through the use of video and various sensors, leveraging computer vision, smart analytics, and machine learning. This data is relayed to healthcare providers, allowing them to make informed treatment decisions tailored to individual patients. The solution has been crafted in collaboration with leading hospitals in Finland, enhancing its reliability and effectiveness in managing epilepsy care.

Valo Therapeutics is an immunotherapy company based in Oxford, United Kingdom, with an additional office in Helsinki, Finland. Founded in 2016, the company focuses on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Its primary platform, PeptiCRAd, is an engineered human oncolytic adenovirus designed to stimulate a systemic anti-tumor T cell response. This innovative approach enables the conversion of oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need for multiple genetically modified viruses. Additionally, Valo Therapeutics is working on other strategies, such as PeptiENV, to enhance therapeutic responses to enveloped oncolytic viruses across various cancer types. By utilizing tumor-specific peptides, the company aims to elicit a robust adaptive immune response, potentially providing lasting immunity against multiple cancers and improving patient outcomes.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Quanturi Oy is a Finnish company founded in 2016 and headquartered in Espoo, specializing in continuous monitoring solutions for fermentable products. The company develops and markets connected objects and systems for data analysis, focusing on agricultural, forestry, and waste management sectors. Its product offerings include wireless monitoring systems for compost temperature, grain management, hay monitoring, and other industrial temperature applications. Quanturi Oy also sells its products online and has expanded its presence to several countries, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium.

Quanturi Oy is a Finnish company founded in 2016 and headquartered in Espoo, specializing in continuous monitoring solutions for fermentable products. The company develops and markets connected objects and systems for data analysis, focusing on agricultural, forestry, and waste management sectors. Its product offerings include wireless monitoring systems for compost temperature, grain management, hay monitoring, and other industrial temperature applications. Quanturi Oy also sells its products online and has expanded its presence to several countries, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium.

Carbo Culture Oy, founded in 2016 and based in Helsinki, Finland, specializes in producing biochar from waste biomass by employing a carbon sequestration process that captures carbon dioxide from the atmosphere. The company transforms orchard waste into high-quality biochar using patented reactors, which serves various applications, including soil enhancement and contamination remediation. This biochar helps improve soil health by retaining water and nutrients, while also supporting beneficial microorganisms. Additionally, Carbo Culture's innovative approach generates renewable energy and contributes to the creation of significant carbon credits, promoting sustainable practices in agriculture and construction.

Surgify is engaged in the development of an innovative technology aimed at enhancing bone surgery outcomes. This technology focuses on protecting proximal soft structures during surgical procedures, thereby minimizing the risk of complications such as bleeding, infections, and nerve injuries. By collaborating closely with the Neurosurgical Department of Helsinki University Central Hospital, Surgify ensures that its solutions are informed by the needs of clinicians. The company is currently preparing to commercialize its technology, with support from the Finnish Funding Agency for Innovation. Through its advancements, Surgify aims to reduce patient suffering and improve overall quality of life for individuals undergoing bone surgery.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Surgify is engaged in the development of an innovative technology aimed at enhancing bone surgery outcomes. This technology focuses on protecting proximal soft structures during surgical procedures, thereby minimizing the risk of complications such as bleeding, infections, and nerve injuries. By collaborating closely with the Neurosurgical Department of Helsinki University Central Hospital, Surgify ensures that its solutions are informed by the needs of clinicians. The company is currently preparing to commercialize its technology, with support from the Finnish Funding Agency for Innovation. Through its advancements, Surgify aims to reduce patient suffering and improve overall quality of life for individuals undergoing bone surgery.

Comptek Solutions Oy, founded in 2017 and based in Turku, Finland, specializes in developing advanced surface engineering technology known as Kontrox. This quantum-level process is designed to create defect-free surfaces for compound semiconductor devices, addressing the critical issues of oxidation that lead to performance limitations in products like MicroLEDs, lasers, and power electronics. By improving the crystalline quality of III-V-based semiconductors, Kontrox technology significantly enhances device performance, achieving notable improvements such as a 250% increase in efficiency and a 90-fold reduction in power consumption. Comptek Solutions has applications across various sectors, including optoelectronics and radio frequency technologies. The company has gained recognition for its innovative approach, receiving a Horizon2020 SME phase I grant from the EU in 2018 and being shortlisted as a top semiconductor spinoff in the inaugural Spinoff Prize competition by Nature Research in 2020.

Comptek Solutions Oy, founded in 2017 and based in Turku, Finland, specializes in developing advanced surface engineering technology known as Kontrox. This quantum-level process is designed to create defect-free surfaces for compound semiconductor devices, addressing the critical issues of oxidation that lead to performance limitations in products like MicroLEDs, lasers, and power electronics. By improving the crystalline quality of III-V-based semiconductors, Kontrox technology significantly enhances device performance, achieving notable improvements such as a 250% increase in efficiency and a 90-fold reduction in power consumption. Comptek Solutions has applications across various sectors, including optoelectronics and radio frequency technologies. The company has gained recognition for its innovative approach, receiving a Horizon2020 SME phase I grant from the EU in 2018 and being shortlisted as a top semiconductor spinoff in the inaugural Spinoff Prize competition by Nature Research in 2020.

Carbo Culture Oy, founded in 2016 and based in Helsinki, Finland, specializes in producing biochar from waste biomass by employing a carbon sequestration process that captures carbon dioxide from the atmosphere. The company transforms orchard waste into high-quality biochar using patented reactors, which serves various applications, including soil enhancement and contamination remediation. This biochar helps improve soil health by retaining water and nutrients, while also supporting beneficial microorganisms. Additionally, Carbo Culture's innovative approach generates renewable energy and contributes to the creation of significant carbon credits, promoting sustainable practices in agriculture and construction.

IQM Quantum Computers, founded in 2018 and headquartered in Espoo, Finland, specializes in developing and manufacturing hardware systems for quantum computing. The company focuses on scalable hardware solutions utilizing superconducting technology to build quantum processors for universal quantum computers. By concentrating on practical applications, IQM aims to enhance quantum computing capabilities and address challenges faced by various industries and society. As a spin-out from Aalto University and the VTT Technical Research Centre of Finland, IQM has achieved significant advancements in areas such as thermal management, which are crucial for improving computational speed and information accuracy. The company's innovations position it as a leader in the global pursuit of large-scale quantum computing solutions. IQM also offers access to its hardware for research laboratories and supercomputing centers, helping businesses reduce error rates that currently limit computing performance.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

Neuro Event Labs Oy is a Finnish medical technology company founded in 2015 and based in Tampere. The company specializes in developing artificial intelligence-powered software that monitors epilepsy patients both at home and in clinical settings. Its primary product collects and analyzes accurate data on epilepsy seizures through the use of video and various sensors, leveraging computer vision, smart analytics, and machine learning. This data is relayed to healthcare providers, allowing them to make informed treatment decisions tailored to individual patients. The solution has been crafted in collaboration with leading hospitals in Finland, enhancing its reliability and effectiveness in managing epilepsy care.

IQM Quantum Computers, founded in 2018 and headquartered in Espoo, Finland, specializes in developing and manufacturing hardware systems for quantum computing. The company focuses on scalable hardware solutions utilizing superconducting technology to build quantum processors for universal quantum computers. By concentrating on practical applications, IQM aims to enhance quantum computing capabilities and address challenges faced by various industries and society. As a spin-out from Aalto University and the VTT Technical Research Centre of Finland, IQM has achieved significant advancements in areas such as thermal management, which are crucial for improving computational speed and information accuracy. The company's innovations position it as a leader in the global pursuit of large-scale quantum computing solutions. IQM also offers access to its hardware for research laboratories and supercomputing centers, helping businesses reduce error rates that currently limit computing performance.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

Neuro Event Labs Oy is a Finnish medical technology company founded in 2015 and based in Tampere. The company specializes in developing artificial intelligence-powered software that monitors epilepsy patients both at home and in clinical settings. Its primary product collects and analyzes accurate data on epilepsy seizures through the use of video and various sensors, leveraging computer vision, smart analytics, and machine learning. This data is relayed to healthcare providers, allowing them to make informed treatment decisions tailored to individual patients. The solution has been crafted in collaboration with leading hospitals in Finland, enhancing its reliability and effectiveness in managing epilepsy care.

Aiforia Technologies, founded in 2013 as a spin-off from the Finnish Institute for Molecular Medicine at the University of Helsinki, specializes in cloud-based microscopy and pathology. The company offers the Aiforia® Platform, which combines deep learning artificial intelligence with high-performance cloud computing to enhance image-based diagnostics. Aiforia's solutions aim to increase efficiency and scalability in medical image analysis, supporting pathologists and scientists in both preclinical and clinical settings. By providing highly accurate and consistent data, Aiforia facilitates new discoveries and clinical decision-making across various disciplines, including oncology and neuroscience. The platform's image-agnostic capabilities allow it to extend its applications beyond traditional boundaries, positioning Aiforia as a leader in advancing medical imaging technology.

SSH Communications Security Oyj specializes in enterprise cybersecurity solutions aimed at helping organizations, particularly in the financial sector, manage and secure access to critical data, applications, and services globally. Founded in 1995 by Tatu Ylönen, who developed the widely adopted Secure Shell protocol, the company offers a range of products, including PrivX for access management in multi-cloud environments, Universal SSH Key Manager for managing SSH keys and certificates, Tectia SSH for secure file transfers and remote administration, and NQX Firewall for high-security applications. With a customer base exceeding 3,000 worldwide, SSH Communications Security focuses on providing security, compliance, and operational efficiency in complex enterprise environments. The company operates through direct sales and online channels, deriving a significant portion of its revenue from Finland while serving clients across various regions, including the Americas, Asia-Pacific, Europe, and the Middle East.

RePack is a company based in Helsinki, Finland, that specializes in manufacturing reusable and recyclable packaging solutions for online retailers and shoppers. Founded in 2013, RePack offers durable packaging bags made from materials such as polypropylene, polyethylene, and cardboard, which can be conveniently returned for recycling. The innovative system encourages customers to participate in sustainability efforts by rewarding them with vouchers for future purchases when they return the packaging. This model not only enhances the customer experience but also aims to reduce waste and carbon emissions. RePack's packaging is designed to be folded into a letter-sized format for easy return via local postal systems, making it a practical option for eCommerce businesses looking to demonstrate their commitment to sustainability.

Medicortex Finland is focused on developing a non-invasive, point-of-care diagnostic test for Traumatic Brain Injury (TBI) and concussions. Traditional diagnostic methods, such as CT and MRI scans, struggle to accurately diagnose mild TBIs. To address this, Medicortex is identifying brain injury biomarkers that can be detected from urine and saliva, with plans to incorporate these biomarkers into a hand-held diagnostic kit that provides rapid and reliable results without the need for medical professionals' interpretation. The company aims to collaborate with larger diagnostic firms for manufacturing and distribution. Its target customers include hospitals, emergency rooms, paramedics, military personnel, sports teams, pharmaceutical companies, and insurance providers. Medicortex has achieved significant milestones, including reaching Phase II clinical studies for its biomarker and receiving grant funding from the US Department of Defense, the European Union, and the Finnish Government.

Imaqen Ltd. is a Finnish healthcare technology company developing a new pre-screening solution for early detection of cancer. The innovation offers a non-invasive patient examination and it is suitable for use in wide range of healthcare facilities. The utilised method is protected by patents. Their team consists of experienced diagnostic imaging and clinical research professionals with solid track records in successful product development and global sales and marketing.

Valtavalo Ltd, founded in 2008, specializes in the development, manufacture, and supply of energy-efficient LED lighting solutions in Finland and internationally. As the largest LED tube manufacturer in the Northern Countries, Valtavalo focuses on high-volume production and large clients, allowing the company to offer competitive pricing on advanced lighting technologies that were previously considered too costly. Their product line features long-lifetime LED lighting tubes with replaceable light sources, which significantly reduce energy consumption and lower both installation and maintenance costs for users.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.